Current Liabilities decreased faster than Zymergen's Cash & cash equivalent, this led to improvement in Zymergen's Quick Ratio to 4.09, Quick Ratio remained below Zymergen Inc. average.

Within Medical Laboratories industry 17 other companies have achieved higher Quick Ratio than Zymergen in second quarter 2022. While Quick Ratio total ranking has improved so far during the Q2 2022 to 1162, from total ranking in the first quarter 2022 at 1202.

Explain Quick Ratio?
How much Cash & cash equivalents ZY�s has?
What are ZY�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

ZY Quick Ratio	(Jun 30 2022) Q2	(Mar 31 2022) Q1	(Dec 31 2021) Q4	(Sep 30 2021) Q3	(Jun 30 2021) Q2
Y / Y Current Liabilities Change	7.87 %	131.52 %	-41.91 %	-	-
Y / Y Cash & cash equivalent Change	-63.04 %	178.42 %	83.68 %	-	-
Quick Ratio MRQ	4.09	3.81	5.59	4.19	11.94
ZY's Total Ranking	# 1162	# 1202	# 909	# 1208	# 446
Seq. Current Liabilities Change	-41 %	28.05 %	-41.64 %	144.62 %	26.65 %
Seq. Cash & cash equivalent Change	-36.63 %	-12.72 %	-22.19 %	-14.1 %	377.33 %

Quick Ratio second quarter 2022 Company Ranking
Within:	No.
Medical Laboratories Industry	# 18
Healthcare Sector	# 559
Overall Market	# 1162

Quick Ratio Statistics
High	Average	Low
11.94	5.46	3.17
(Jun 30 2021)		(Mar 31 2021)

Financial Statements
Zymergen's Current Liabilities	$ 52 Millions	Visit ZY's Balance sheet
Zymergen's Cash & cash equivalent	$ 214 Millions	Visit ZY's Balance sheet
Source of ZY's Sales		Visit ZY's Sales by Geography

Cumulative Zymergen's Quick Ratio

ZY's Quick Ratio for the trailling 12 Months

ZY Quick Ratio	(Jun 30 2022) 12 Months	(Mar 31 2022) 12 Months	(Dec 31 2021) 12 Months	(Sep 30 2021) 12 Months	(Jun 30 2021) 12 Months
Y / Y Current Liabilities TTM Growth	59.65 %	106.39 %	130.44 %	-	-
Y / Y Cash & cash equivalent TTM Growth	57.64 %	442.53 %	652.18 %	-	-
Quick Ratio TTM	4.37	5.54	5.77	4.34	4.42
Total Ranking TTM	# 5163	# 758	# 708	# 814	# 0
Seq. Current Liabilities TTM Growth	1.17 %	18.34 %	-15.39 %	57.59 %	30.8 %
Seq. Cash & cash equivalent TTM Growth	-20.26 %	13.66 %	12.52 %	54.59 %	174.41 %

Quick ratio ranking by company, industry and sector >> Back to ZY Financial Strength Comparisons >> Go to Compare ZY Quick Ratio to its Competitors

On the trailing twelve months basis Due to cut in Current Liabilities in the Q2 2022 to $52.20 millions, cumulative Quick Ratio decreased to 4.37 below the Zymergen Inc. average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Medical Laboratories industry 49 other companies have achieved higher Quick Ratio than Zymergen. While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the first quarter 2022 from 758 to 5163.

Explain Quick Ratio?
How much Cash & cash equivalents ZY�s has?
What are ZY�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Medical Laboratories Industry	# 50
Healthcare Sector	# 1168
Within the Market	# 5163

trailing twelve months Quick Ratio Statistics
High	Average	Low
5.52	5.06	4.28
(Dec 31 2021)		(Jun 30 2022)

Companies with similar Quick Ratio in the quarter ending Jun 30 2022, within Medical Laboratories Industry	Quick Ratio	Jun 30 2022 MRQ Cash & cash equivalent	Jun 30 2022 MRQ Current Liabilities
Castle Biosciences Inc	9.93	$ 273.166 Millions	$ 27.519 Millions
Exagen Inc	8.42	$ 76.387 Millions	$ 9.075 Millions
Absci Corp	8.35	$ 206.021 Millions	$ 24.659 Millions
Butterfly Network Inc	8.14	$ 310.802 Millions	$ 38.184 Millions
Science 37 Holdings Inc	7.08	$ 148.329 Millions	$ 20.936 Millions
Viridian Therapeutics Inc	6.07	$ 129.914 Millions	$ 21.388 Millions
WEED, INC.	5.75	$ 0.821 Millions	$ 0.143 Millions
Personalis Inc	5.63	$ 233.490 Millions	$ 41.506 Millions
Invitae Corporation	5.22	$ 726.763 Millions	$ 139.251 Millions
Guardant Health Inc	5.09	$ 853.690 Millions	$ 167.755 Millions
Zymergen Inc.	4.09	$ 213.558 Millions	$ 52.196 Millions
Caredx Inc	3.90	$ 306.220 Millions	$ 78.456 Millions
Burning Rock Biotech Limited	3.59	$ 171.803 Millions	$ 47.833 Millions
Nano X Imaging Ltd	3.10	$ 77.624 Millions	$ 25.074 Millions
Veracyte Inc	3.00	$ 153.447 Millions	$ 51.222 Millions
Incyte Corporation	2.95	$ 2,722.425 Millions	$ 923.638 Millions
Natera Inc	2.92	$ 638.737 Millions	$ 218.562 Millions
Aclarion Inc	2.75	$ 3.793 Millions	$ 1.381 Millions
American Shared Hospital Services	2.58	$ 11.967 Millions	$ 4.630 Millions
Biocept Inc	2.39	$ 22.928 Millions	$ 9.613 Millions
Fulgent Genetics Inc	1.89	$ 138.780 Millions	$ 73.467 Millions
Exact Sciences Corporation	1.74	$ 728.044 Millions	$ 417.518 Millions
Renalytix Plc	1.71	$ 23.800 Millions	$ 13.921 Millions
Vyant Bio Inc	1.56	$ 11.702 Millions	$ 7.507 Millions
Capforce Inc	1.15	$ 16.587 Millions	$ 14.394 Millions
Bionexus Gene Lab Corp	0.90	$ 1.340 Millions	$ 1.488 Millions
Centogene N v	0.90	$ 40.265 Millions	$ 44.857 Millions
Nrc Health	0.83	$ 32.974 Millions	$ 39.587 Millions

Date modified: 2026-09-26T07:39:43+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.